Answers are grounded in this paper and cite their sources.
A simple chemiluminescent immunoassay (CLIA) for urinary albumin has been developed based on the use of a chemiluminescent acridinium ester-labelled human albumin and a commercially available antiserum. It includes two incubation steps and a second polyethylene glycol-assisted antibody separation. The sensitivity of detection is 0.016 mg/l, the assay working range is 0.1-5 mg/l, and the inter-assay CVs are less than or equal to 15%. Using 10- and 50-fold sample dilutions in assay buffer, a wide working range (1-250 mg/l) is obtained covering normal and pathological conditions. Timed overnight urine samples (bed rest conditions) were collected on three consecutive days for each patient. Albumin excretion rate (AER) was 4.7 +/- 2.7 micrograms/min (mean +/- SD), range 1-15.9 micrograms/min in 36 healthy subjects (17 male, 19 female, ages 4-56 years), with day-to-day variations of 28.5 +/- 20% (mean +/- SD), range 3.3-76.1%. The use of an acridinium ester as a chemiluminescent (CL) label overcomes the disadvantages of short shelf-life and health and safety hazards associated with radioisotopes. Results compare favourably with those obtained using a commercially available RIA kit.
No takes yet. Share an insight, caveat, or question.
Bagazgoitia et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: